InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Key Stats

• Today's Range: $2.20 to $2.29
• 50-Day Range: $2.19 to $2.70
• 52-Week Range: $1.99 to $3.80
• Volume: 44,755 shs
• Average Volume: 66,507 shs
• Market Capitalization: $69.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 53% of companies evaluated by MarketBeat, and ranked 353rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

InspireMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.07% of the float of InspireMD has been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently decreased by 4.40%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.07% of the float of InspireMD has been sold short.

Short Interest Ratio / Days to Cover

InspireMD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InspireMD has recently decreased by 4.40%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for InspireMD this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.06% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NSPR Stock Analysis - Frequently Asked Questions

How have NSPR shares performed this year?

InspireMD's stock was trading at $2.63 on January 1st, 2025. Since then, NSPR shares have decreased by 14.3% and is now trading at $2.2550.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) issued its earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.04. The business earned $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative trailing twelve-month return on equity of 69.42%.

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NSPR
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.50
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +99.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.92 million
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $7.03 million
• Price / Sales: 9.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 30,635,000
• Free Float: 18,332,000
• Market Cap: $69.08 million
• Optionable: Optionable
• Beta: 0.57